Inflammation clustering with insulin resistance
What These Measurements Mean Together
Published epidemiological cohorts commonly describe low-grade systemic inflammation clustering with hyperinsulinemia and impaired glucose tolerance. Adipokines, ectopic lipid accumulation, and free fatty acid overflow drive macrophage recruitment, stimulating low-grade hepatic CRP release. Where CRP and glycemic markers move together they track the same underlying metabolic state; exercise, diet and weight change alter that state. CRP is the readout, not the target.
What This Does NOT Mean
What these results cannot tell you:
- × That metabolic markers directly caused the inflammation, or the reverse.
- × That a specific clinical diagnosis (such as metabolic syndrome or type 2 diabetes) is established.
- × That lowering hs-CRP is itself a validated clinical goal — CRP-lowering has not been established as causal.
What to Consider & Next Steps
Engage in a clinician conversation focused on metabolic, dietary, and physical activity drivers where the therapeutic evidence base is robust.
Frequently Asked Questions
What does this pattern mean when evaluating blood test results?
Published epidemiological cohorts commonly describe low-grade systemic inflammation clustering with hyperinsulinemia and impaired glucose tolerance. Adipokines, ectopic lipid accumulation, and free fatty acid overflow drive macrophage recruitment, stimulating low-grade hepatic CRP release. Where CRP and glycemic markers move together they track the same underlying metabolic state; exercise, diet and weight change alter that state. CRP is the readout, not the target.
What should this pattern NOT be used to infer?
That metabolic markers directly caused the inflammation, or the reverse. That a specific clinical diagnosis (such as metabolic syndrome or type 2 diabetes) is established. That lowering hs-CRP is itself a validated clinical goal — CRP-lowering has not been established as causal.
What is the recommended retesting frequency, and what should you consider next?
Engage in a clinician conversation focused on metabolic, dietary, and physical activity drivers where the therapeutic evidence base is robust.
Summary
- Interpretation Rule
- Interprets Panel, Not Person
Scientific Citations (4)
- [1] Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999;19(4):972-978.
- [2] Ellulu MS, Patimah I, Khaza'ai H, Rahmat A, Abed Y. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci. 2017;13(4):851-863.
- [3] López-Bermejo A, et al. Sex-specific, independent associations of insulin resistance with erythrocyte sedimentation rate in apparently healthy subjects. Thromb Haemost. 2007;97(2):240-244.
- [4] Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207.
Related Patterns
Track Your Inflammation — Cohort Now Forming
Track your own inflammatory gene expression over time. Reserve your spot in the Inflammation Compass founding cohort today to lock in early pricing before the general public.